Trial site
Lenox Hill Brain Tumor Center
New York, New York 10075, United StatesNot linked to an institution yet
- 8running trials
- 1closed trial
The trials here
What the 11 trials at this site are about, from their registry records.
- Phase
- Phase 1/24 trials
- Phase 11 trial
- Phase 21 trial
- Phase 31 trial
- Status
- Recruiting8 trials
- Suspended2 trials
- Completed1 trial
- Lead sponsor
- Northwell Health11 trials
Running trials
Recruiting
Observational Connectomics in Adults Undergoing Resection of WHO II-IV Glioma
NCT07927595· Northwell Health· Source
Contact: Randy D'Amico, MD
Recruiting
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
NCT05954858· Northwell Health· Source
Contact: John Boockvar, MD
Recruiting
Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)
NCT05979064· Northwell Health· Source
Contact: John Boockvar, MD
Recruiting
Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM
NCT05271240· Phase 3· Northwell Health· Source
Contact: John Boockvar, MD
Recruiting
Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM
NCT03213002· Phase 1/2· Northwell Health· Source
Contact: Tamika Wong, MPH
Recruiting
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
NCT02861898· Phase 1/2· Northwell Health· Source
Contact: John Boockvar, MD
Recruiting
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
NCT02800486· Phase 2· Northwell Health· Source
Contact: John Boockvar, MD
Recruiting
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
NCT01269853· Phase 1/2· Northwell Health· Source
Contact: John Boockvar, MD
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error